Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 351

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 351
---
                                                                                                      
  BSA 2013                                         46,360       46,360                                                      
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  BSA 2014                                         75,000       75,000       75,000       75,000                            
  BSA 2015-1                                       70,000       70,000       70,000       70,000       70,000       70,000  
  BSA 2015-2                                       14,200       14,200       14,200       14,200       14,200       14,200  
  BSA 2017                                         37,000       37,000       37,000       37,000       37,000       37,000  
  BSA 2022-1                                        8,260        8,260        8,260        8,260        8,260        8,260  
  BSA 2023-1                                                                 38,000       38,000       38,000       38,000  
  TOTAL                                           250,820      250,820      242,460      204,460      167,460      167,460  

F-68

BSAAR

BSAAR are securities whose subscription price and exercise price are fixed at their fair value as determined by an expert. The BSAAR subscription therefore represents an investment on the part of the beneficiary. At the end of the exercise period, if they have not been exercised, the BSAAR becomes void. The Company benefits from a clause called «forcing» making it possible to encourage holders to exercise their redeemable equity warrants when the market price exceeds the exercise price and reaches a threshold defined in the BSAAR issuance agreement. The Company may, then, subject to a time period for notifying holders that will permit them to exercise the BSAAR, decide to reimburse the warrants not exercised at a unit price equal to the BSAAR acquisition price paid by its holder.

Details of BSAAR

BSAAR. The methodology used to estimate the fair value of the BSAAR is similar to the one used to estimate the fair value of the BSA, except for the following:

Expected Term. Unlike the BSA, the Company does not have sufficient historical experience for the BSAAR.